API | elapegademase-lvlr

elapegademase-lvlr (revcovi) Report issue

Biologics Recombinant protein Orphan Drug ^FDA Approved ^FDA Fast Track ^FDA

AACT Drugs@FDA PubChem

Active Ingredient History

NOW

Elapegademase, sold under the brand name Revcovi, is a medication for the treatment of the rare disease adenosine deaminase deficiency-SCID in children and adults. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
elapegademase

More Chemistry

Pharmacology

Mechanisms of Action:
- Adenosine deaminase (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Missing data
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$3701.9550

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

elapegademase-lvlr | ezn-2279

Organizations (2)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (2)

Primary Immunodeficiency Diseases (approved 2018)

Severe Combined Immunodeficiency

Experimental Indications - Clinical Trial Phases 1-4 (2)

Adenosine Deaminase (Phase 3)

Severe Combined Immunodeficiency (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 1
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue